Cook, Robert O <br/><br/>
Reduced adverse event profile of orally inhaled DHE (MAP0004) vs IV DHE: potential mechanism.  [electronic resource] 

 -  Headache   
 - 1423-34 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>1526-4610 
<br/><br/><label>Standard No.: </label>10.1111/j.1526-4610.2009.01510.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Inhalation<br/>Administration, Oral<br/>Animals<br/>Cross-Over Studies<br/>Dihydroergotamine--administration & dosage<br/>Dizziness--chemically induced<br/>Guinea Pigs<br/>Humans<br/>Infusions, Intravenous<br/>Nausea--chemically induced<br/>Protein Binding--physiology<br/>Receptors, Serotonin--metabolism